Resumen: Disorders resulting from mitochondrial DNA (mtDNA) mutations, including nonsense mutations, do not yet have causal treatments. As we discuss here, read-through therapies appear to be a promising approach to the treatment of disorders arising from nuclear DNA (nDNA) nonsense mutations. The genetics of mitochondrial DNA suggest that this therapy will also be successful in the treatment of mitochondriopathies. Idioma: Inglés DOI: 10.1016/j.drudis.2012.04.012 Año: 2012 Publicado en: DRUG DISCOVERY TODAY 17, 19-20 (2012), 1063-1067 ISSN: 1359-6446 Factor impacto JCR: 6.551 (2012) Categ. JCR: PHARMACOLOGY & PHARMACY rank: 12 / 259 = 0.046 (2012) - Q1 - T1 Tipo y forma: Article (Published version) Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.) Área (Departamento): Proy. investigación DEA (Dpto. Bioq.Biolog.Mol. Celular) Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Exportado de SIDERAL (2024-01-25-15:15:41)